Skip to main content
. 2023 Jan 3;13(1):128. doi: 10.3390/life13010128

Table 1.

Clinical applications of EIPH measurements.

Diagnostic Tool/Parameters Diseases Clinical Applications—“Strengths” Limitations—“Weaknesses”
ESE
(TRVmax
PASP calculation)
PAH
  • (1)

    Predictor of PH in pts with systemic sclerosis with normal resting mPAP.

  • (2)

    Higher risk of hospitalizations in pts with myelodysplastic syndrome.

  • (3)

    Helpful for decision-making in asymptomatic pts with severe MS.

  • (4)

    Helpful for diagnosis and risk stratification in asymptomatic pts with severe MR.

  • (5)

    Helpful for diagnosis and risk stratification in asymptomatic pts with severe AS.

  • (6)

    Index of worse prognosis in pts with HFrEF.

  • (7)

    Index of worse prognosis in pts with HCM.

  • (1)

    PASP influenced by pulmonary function, exercise capacity and age.

  • (2)

    Sometimes failure to get sufficient Doppler signal for TRVmax.

  • (3)

    Inability to perform exercise test in older patients or those with orthopedic problems.

  • (4)

    Need for cut-off value determination and validation.

MS
MR
AS
HFrEF
HCM
CPET
(VE/VCO2,
peak VO2,
PETCO2)
PAH
  • (1)

    Good correlation with RHC for PAH diagnosis.

  • (2)

    Normal values exclude PAH.

  • (1)

    Patients’ discomfort.

  • (2)

    Complex interpretation.

  • (3)

    Need for cut-off value determination and validation.

RHC during exercise
(mPAP, wPAP)
MR
  • (1)

    Current gold standard method.

  • (2)

    Helpful for diagnosis and prognosis of MR.

  • (3)

    Helpful for diagnosis of HFpEF.

  • (1)

    Invasive technique. Potential complications and high facilities demand.

  • (2)

    Not easily repeatable.

  • (3)

    Artifacts and catheter whip during exercise.

HFpEF

AS, aortic stenosis; CPET, cardiopulmonary exercise testing; ESE, exercise–stress echocardiography; HCM, hypertrophic cardiomyopathy; MR, mitral regurgitation; HFpEF, heart failure preserved ejection fraction; HFrEF, heart failure reduced ejection fraction; mPAP, mean pulmonary artery pressure; MS, mitral stenosis; PASP, pulmonary artery systolic pressure; peak VO2, peak oxygen consumption; PETCO2, extrapolated end-tidal carbon dioxide tension; pts, patients; PAH, pulmonary artery hypertension; RHC; right heart catheterization; TRVmax, tricuspid regurgitation maximum velocity; VE/VCO2, ventilation to carbon dioxide production relationship; wPAP, wedge PAP.